KOTOLOVÁ, Hana, Jan JUŘICA, Tomáš HAMMER, Ondřej ZENDULKA, Martina NOVÁKOVÁ, Pavla KAREŠOVÁ, Kateřina KUBOVÁ and Jakub VYSLOUŽIL. Parenteral depot dosage forms in psychiatry and the development of a new particulate dosage form of mirtazapine. In 70th Czech-Slovak Pharmacological Days. 2022. ISSN 2453-6725. Available from: https://dx.doi.org/10.2478/afpuc-2022-0008.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Parenteral depot dosage forms in psychiatry and the development of a new particulate dosage form of mirtazapine
Name in Czech Parenterální depotní lékové formy v psychiatrii a vývoj nové částicové lékové formy mirtazapinu
Name (in English) Parenteral depot dosage forms in psychiatry and the development of a new particulate dosage form of mirtazapine
Authors KOTOLOVÁ, Hana (203 Czech Republic, belonging to the institution), Jan JUŘICA (203 Czech Republic, belonging to the institution), Tomáš HAMMER (203 Czech Republic, belonging to the institution), Ondřej ZENDULKA (203 Czech Republic, belonging to the institution), Martina NOVÁKOVÁ (203 Czech Republic, belonging to the institution), Pavla KAREŠOVÁ, Kateřina KUBOVÁ (203 Czech Republic, belonging to the institution) and Jakub VYSLOUŽIL (203 Czech Republic, belonging to the institution).
Edition 70th Czech-Slovak Pharmacological Days, 2022.
Other information
Original language Czech
Type of outcome Conference abstract
Field of Study 30104 Pharmacology and pharmacy
Confidentiality degree is not subject to a state or trade secret
WWW European Pharmaceutical Journal, volume 69, issue s1, 2022
RIV identification code RIV/00216224:14160/22:00126273
Organization unit Faculty of Pharmacy
ISSN 2453-6725
Doi http://dx.doi.org/10.2478/afpuc-2022-0008
Keywords (in Czech) depotní lékové formy; mirtazapin; neuropsychiatrické onemocnění; nonadherence
Keywords in English depot dosage forms; mirtazapine; neuropsychiatric illness; nonadherence
Tags rivok, ÚAF, ÚFT, ÚFTo
Tags International impact
Changed by Changed by: JUDr. Sabina Krejčiříková, učo 383857. Changed: 31/1/2023 15:18.
Abstract
The main advantages of depot psychotropic drugs include improved adherence to treatment, absence of problems with absorption from the gastrointestinal tract, circumvention of first-pass metabolism and absence of risk of accidental or intentional overdose. The development of depot dosage forms is currently focused on the study of microparticles. The drug content, morphology and dissolution test were evaluated for the prepared microparticles containing mirtazapine. The pharmacokinetic profile of administered microparticles was determined based on frequent sampling. The serum was further used to determine liver tests, the lipid spectrum and selected adipokines.
Abstract (in English)
The main advantages of depot psychotropic drugs include improved adherence to treatment, absence of problems with absorption from the gastrointestinal tract, circumvention of first-pass metabolism and absence of risk of accidental or intentional overdose. The development of depot dosage forms is currently focused on the study of microparticles. The drug content, morphology and dissolution test were evaluated for the prepared microparticles containing mirtazapine. The pharmacokinetic profile of administered microparticles was determined based on frequent sampling. The serum was further used to determine liver tests, the lipid spectrum and selected adipokines.
Links
MUNI/A/1309/2021, interní kód MUName: Vývoj a studium nové částicové lékové formy s prodlouženým uvolňováním mirtazapinu (Acronym: MIRTHTM)
Investor: Masaryk University
MUNI/A/1440/2021, interní kód MUName: Preklinický a klinický výzkum Farmakologického ústavu v oblasti farmakokinetiky, neurobiologie závislostí a personalizované farmakoterapie v onkologii (Acronym: Farm-Pre-Klin)
Investor: Masaryk University
PrintDisplayed: 31/7/2024 22:26